X4 Pharmaceuticals Inc
XFOR5.335USD
+5.145+2707.89%
Cierre 04/28, 16:00（ET）Cotizaciones retrasadas 15 min
912.00MCap. mercado
PérdidaP/E TTM
Más Datos de X4 Pharmaceuticals Inc Compañía
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Información de la empresa
Código de la empresaXFOR
Nombre de la empresaX4 Pharmaceuticals Inc
Fecha de salida a bolsaNov 16, 2017
Fundada en2010
Director ejecutivoDr. Paula Ragan, Ph.D.
Número de empleados143
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 16
Dirección61 North Beacon Street
CiudadBOSTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02134
Teléfono18575298300
Sitio Webhttps://www.x4pharma.com/
Código de la empresaXFOR
Fecha de salida a bolsaNov 16, 2017
Fundada en2010
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Dr. Christophe Arbet-engels, Ph.D.
Dr. Christophe Arbet-engels, Ph.D.
Chief Medical Officer
Chief Medical Officer
28.81K
+5.98K%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
4.31K
-82.28%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
2.56K
-36.98%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
1.72K
-46.55%
Mr. David W.J. Mcgirr
Mr. David W.J. Mcgirr
Independent Director
Independent Director
--
--
Dr. Murray W. Stewart, M.D.
Dr. Murray W. Stewart, M.D.
Director
Director
--
--
Ms. Francoise De Craecker
Ms. Francoise De Craecker
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
Managing Director
Managing Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Dr. Christophe Arbet-engels, Ph.D.
Dr. Christophe Arbet-engels, Ph.D.
Chief Medical Officer
Chief Medical Officer
28.81K
+5.98K%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
4.31K
-82.28%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
2.56K
-36.98%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
1.72K
-46.55%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: dom., 23 de feb
Hora de actualización: dom., 23 de feb
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Bain Capital Life Sciences Investors, LLC
9.74%
New Enterprise Associates (NEA)
8.63%
BlackRock Institutional Trust Company, N.A.
5.91%
The Vanguard Group, Inc.
4.72%
Acorn Capital Advisors, LLC
4.21%
Other
66.79%
Estadísticas de accionistas
Accionista
Proporción
Bain Capital Life Sciences Investors, LLC
9.74%
New Enterprise Associates (NEA)
8.63%
BlackRock Institutional Trust Company, N.A.
5.91%
The Vanguard Group, Inc.
4.72%
Acorn Capital Advisors, LLC
4.21%
Other
66.79%
Tipo
Accionista
Proporción
Investment Advisor
25.05%
Investment Advisor/Hedge Fund
11.85%
Venture Capital
8.63%
Hedge Fund
5.73%
Private Equity
4.92%
Individual Investor
2.32%
Research Firm
1.96%
Bank and Trust
0.09%
Pension Fund
0.04%
Other
39.41%
Participación institucional
Hora de actualización: mié., 5 de mar
Hora de actualización: mié., 5 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
216
105.29M
60.63%
-54.29M
2024Q4
216
103.66M
60.78%
-53.08M
2024Q3
212
110.90M
65.83%
-43.36M
2024Q2
209
114.19M
68.28%
-40.11M
2024Q1
203
115.38M
69.15%
-30.64M
2023Q4
192
109.42M
65.98%
-32.86M
2023Q3
189
132.64M
89.63%
+450.20K
2023Q2
191
133.25M
115.52%
+52.30M
2023Q1
171
81.27M
73.10%
+5.35M
2022Q4
172
79.41M
72.57%
+27.33M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Bain Capital Life Sciences Investors, LLC
16.92M
9.74%
--
--
Dec 31, 2024
New Enterprise Associates (NEA)
14.99M
8.63%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
10.26M
5.91%
-93.42K
-0.90%
Dec 31, 2024
The Vanguard Group, Inc.
8.20M
4.72%
-239.83K
-2.84%
Dec 31, 2024
Acorn Capital Advisors, LLC
7.31M
4.21%
--
--
Dec 31, 2024
OrbiMed Advisors, LLC
7.13M
4.11%
--
--
Dec 31, 2024
Kingdon Capital Management, L.L.C.
4.94M
2.84%
+298.32K
+6.43%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.50M
2.01%
+49.70K
+1.44%
Dec 31, 2024
AXA Investment Managers UK Ltd.
3.07M
1.77%
-4.80K
-0.16%
Dec 31, 2024
State Street Global Advisors (US)
3.06M
1.76%
+104.40K
+3.54%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Simplify Propel Opportunities ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Simplify Propel Opportunities ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
Invesco NASDAQ Future Gen 200 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos